Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 927-932

  Matsunaga, Shinji ^a   Iguchi, Kazuhiro ^a   Usui, Shigeyuki ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bisphosphonate; Cell detachment; Incadronate; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; DNA FRAGMENT; FOCAL ADHESION KINASE; GERANYLGERANIOL; INCADRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEPHOSPHORYLATION;

APOPTOSIS; ASPARTIC ACID; CASPASES; CELL ADHESION; CELL LINE, TUMOR; DIPHOSPHONATES; ETOPOSIDE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MALE; MEVALONIC ACID; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS;

EID: 34247128396     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Francis MD, Russell RG and Fleisch H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264-1266, 1969.
2. Fleisch H: Development of bisphosphonates. Breast Cancer Res 4: 30-34, 2002.
3. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890-3894, 1997.
4. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
5. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000.
6. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001.
7. Nishida S, Kikuichi S, Haga H, Yoshioka S, Tsubaki M, Fujii K and Irimajiri K: Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull 26: 96-100, 2003.
8. Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, Mobilio G and Lo Cascio V: Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134: 1152-1154, 1985.
9. Lahtinen R, Laakso M, Palva I, Virkkunen P and Elomaa I: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340: 1049-1052, 1992.
10. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493, 1996.
11. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791, 1996.
12. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
13. Heidenreich A, Hofmann R and Engelmann UH: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165: 136-140, 2001.
14. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K and Namiki M: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 169: 281-282, 2003.
15. Virtanen SS, Vaananen HK, Harkonen PL and Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62: 2708-2714, 2002.
16. Oades GM, Senaratne SG, Clarke IA, Kirby RS and Colston KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170: 246-252, 2003.
17. Coxon JP, Oades GM, Kirby RS and Colston KW: Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94: 164-170, 2004.
18. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K and Namiki M: Bisphosphonate induces apoptosis and inhibits proosteoclastic gene expression in prostate cancer cells. Int J Urol 13: 593-600, 2006.
19. Valenti MT, Bertoldo F, Dalle Carbonare L, Azzarello G, Zenari S, Zanatta M, Balducci E, Vinante O and Lo Cascio V: The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene? BMC Cancer 6: 49, 2006.
20. Iguchi K, Nakano T, Usui S and Hirano K: Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett 237: 223-233, 2006.
21. Iguchi K, Matsunaga S, Nakano T, Usui S and Hirano K: Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res 26: 2977-2981, 2006.
22. Porter JC and Hogg N: Integrins take partners: cross-talk between integrins and other membrane receptors. Trends Cell Biol 8: 390-396, 1998.
23. Iguchi K, Hirano K and Ishida R: Activation of caspase-3, proteolytic cleavage of DFF and no oligonucleosomal DNA fragmentation in apoptotic Molt-4 cells. J Biochem (Tokyo) 131: 469-475, 2002.
24. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
25. Chapman HA, Wei Y, Simon DI and Waltz DA: Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 82: 291-297, 1999.
26. Wei Y, Yang X, Liu Q, Wilkins JA and Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 144: 1285-1294, 1999.
27. Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994.
28. Meredith JE, Jr., Fazeli B and Schwartz MA: The extracellular matrix as a cell survival factor. Mol Biol Cell 4: 953-961, 1993.
29. Frisch SM, Vuori K, Ruoslahti E and Chan-Hui PY: Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793-799, 1996.
30. van de Water B, Nagelkerke JF and Stevens JL: Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells. J Biol Chem 274: 13328-13337, 1999.
31. Duxbury MS, Ito H, Ashley SW and Whang EE: CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. J Biol Chem 279: 23176-23182, 2004.
32. Bezzi M, Hasmim M, Bieler G, Dormond O and Ruegg C: Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278: 43603-43614, 2003.